For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- MHLW Presents Draft Optimal Use Guidelines for Keytruda: Chuikyo
January 25, 2017
- (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
January 25, 2017
- Boy Develops ADEM after DT Vaccine Shot, No Label Change for Now: Panel
January 25, 2017
- MHLW to Launch New Framework for Dialogue with Pharma Industry
January 24, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- MHLW Advisory Committee to Review Sanofi’s VEGF Inhibitor on Feb. 3
January 24, 2017
- PMDA Risk Communication Update for Atarax, Zelboraf
January 23, 2017
- MHLW Asks Pref. Govt to Conduct On-Site Inspections for Pharmacies, Wholesalers: Minister
January 23, 2017
- Correcting Regional Disparities in Generic Use Important for Achieving Govt’s Targets: Health Policy Bureau Chief
January 23, 2017
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
- MHLW to Take Prompt Action on Counterfeit Issue: Bureau Chief
January 20, 2017
- Details of Approvals to Be Provided to Prefectures Prior to Unannounced Inspections: MHLW Official
January 20, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
- MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda
January 17, 2017
- MHLW Task Force on “Data Health” to Compile Report by Summer
January 16, 2017
- PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
- Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021
January 13, 2017
- MHLW Panel on AI Use in Healthcare Boots Up
January 13, 2017
- Projection-Based Price Cuts, Instead of Ex-Post Reviews, Mooted for New Quarterly Scheme
January 12, 2017
- MHLW Wants Specific Plan by May for Four-Times Yearly Price Review of Indication-Added Drugs
January 12, 2017
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…